Park2 loss was associated with an increased incidence of high-grade PIN and low-grade prostate adenocarcinoma (Figures 7B and 7D), as well as significantly higher numbers of solid thyroid adenocarcinomas (Figure 7C). The gene discussed is PRKN; the disease is prostate adenocarcinoma.